Skip to content
Beacon

THNRAmplify Weight Loss Drug & Treatment ETF

Grow my money2y track recordRanked #2,564 of 2,992 in this goal

Seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index.

By Amplify ETFs · Launched 2024

Annual Cost

0.59%

#3,116 of 5,854 · average

Fund Size

$4M

#5,271 of 5,854 · small

Return (1Y)Goal

+12.6%

Track Record

2 years

#3,488 of 5,854 · seasoned

Performance

Total-return NAV · USD
Growth of $10,000
$11,497+15.0%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Equity

Region

Global

Strategy

Index tracking

Sector

Health care

Focus

Obesity & GLP-1

Index tracked

VettaFi Weight Loss Drug & Treatment Index

What it actually holds

By weight

Concentration

Top 10 holdings = 66.5% of fundconcentrated

Novo Nordisk A/S
11.9%
Eli Lilly & Co
11.6%
Regeneron Pharmaceuticals Inc
6.8%
Amgen Inc
6.3%
Chugai Pharmaceutical Co Ltd
6.0%
CSPC Pharmaceutical Group Ltd
5.0%
Arrowhead Pharmaceuticals Inc
5.0%
AbbVie Inc
4.8%
AstraZeneca PLC
4.7%
Pfizer Inc
4.6%

Asset allocation

Stocks
97.4%
Cash
2.0%
Other
0.6%

By sector

Healthcare
100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
19.0%Moderate

Year-on-year price swings

Max drawdown
-32.5%Severe

Worst peak-to-trough loss

Sharpe (3Y)
Unavailable

Needs 3+ years of history

Sortino (3Y)
Not yet

Needs 3+ years of history

Listing

Exchange
NYSE Arca

Full fund details

Objective
Seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index.
Strategy
Invests at least 80% of net assets in securities that comprise the VettaFi Weight Loss Drug & Treatment Index using a replication strategy, with the option for representative sampling. Focuses on global health care companies involved in weight loss drug development, including pharmaceutical manufacturers and telehealth providers.
Inception date
May 20, 2024
Fund family
Amplify ETFs

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Thematic
Warning

These usually launch after the gains are gone

A theme gets packaged into a fund after it has already run. Over the past 15 years, fewer than one in 10 thematic funds beat a broad global index, and more than three-quarters closed down entirely. The pitch always sounds good. The returns rarely follow.

Sources: Morningstar, 'Global Thematic Funds Landscape' (2022)

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've looked at THNR. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.

See other funds for this goal

Data updated on 2026-08-04